44 related articles for article (PubMed ID: 21116874)
1. Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management.
Carter Y; Sippel RS; Chen H
Oncologist; 2014 Jan; 19(1):34-43. PubMed ID: 24309982
[TBL] [Abstract][Full Text] [Related]
2. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Clemons J; Gao D; Naam M; Breaker K; Garfield D; Flaig TW
Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
[TBL] [Abstract][Full Text] [Related]
3. New targeted therapies for thyroid cancer.
Antonelli A; Fallahi P; Ferrari SM; Ruffilli I; Santini F; Minuto M; Galleri D; Miccoli P
Curr Genomics; 2011 Dec; 12(8):626-31. PubMed ID: 22654562
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction from antineoplastic agents.
Hamnvik OP; Larsen PR; Marqusee E
J Natl Cancer Inst; 2011 Nov; 103(21):1572-87. PubMed ID: 22010182
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-induced severe hypothyroidism with cardiac compromise.
Collinson FJ; Vasudev NS; Berkin L; Khan MM; Selby PJ; Brown JE
Med Oncol; 2011 Dec; 28 Suppl 1():S699-701. PubMed ID: 21116874
[TBL] [Abstract][Full Text] [Related]
6. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
[TBL] [Abstract][Full Text] [Related]
7. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
Mannavola D; Coco P; Vannucchi G; Bertuelli R; Carletto M; Casali PG; Beck-Peccoz P; Fugazzola L
J Clin Endocrinol Metab; 2007 Sep; 92(9):3531-4. PubMed ID: 17595247
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.
Brown RL
Target Oncol; 2011 Dec; 6(4):217-26. PubMed ID: 22101606
[TBL] [Abstract][Full Text] [Related]
10. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
[TBL] [Abstract][Full Text] [Related]
11. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
[TBL] [Abstract][Full Text] [Related]
12. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P
Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
